Key result
Matrix metalloproteinases are strongly linked to HF pathogenesis and represent potential therapeutic targets.
Why the study?
Matrix metalloproteinases are strongly associated with the pathogenesis and pathophysiology of heart failure, but their clinical implications and potential as therapeutic targets require clarification.
Matrix metalloproteinases play a crucial role in heart failure pathophysiology and left ventricular remodeling, making them potential therapeutic targets.
Answers are grounded in this paper and cite their sources.
MMP inhibition merits exploration as a HF target; hypothesis-generating and should not yet change practice.
Heart failure (HF) represents a complex multifactorial syndrome, characterized by crucial structural and functional abnormalities of the myocardium. Matrix metalloproteinases are associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after acute myocardial infarction. There is a strong association between oxidative stress and MMPs in the pathophysiology of HF. As MMPs are strongly associated to the pathogenesis and pathophysiology of HF, several agents have been proposed as potential modulators of these molecules. Classical agents such as statins, angiotensin converting enzyme inhibitors (ACEIS) and beta-blockers and a variety of novel agents have been implicated in the pathogenesis and progression of heart failure via the matrix metalloproteinases pathway and consist of possible future therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Tousoulis et al. (2012) conducted a review in Heart failure. Matrix metalloproteinases was evaluated. Matrix metalloproteinases are strongly associated with the pathogenesis and pathophysiology of heart failure, representing potential future therapeutic targets for various pharmacological agents.
Synapse has enriched 10 related papers. Consider them for comparative context: